Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
71 hedge funds and large institutions have $186M invested in Taro Pharmaceutical Industries Ltd. in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
85% more capital invested
Capital invested by funds: $101M → $186M (+$85.2M)
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
15% more funds holding
Funds holding: 62 → 71 (+9)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $800K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.19M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.59M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.8M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$1.9M |
| 2 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$790K |
| 3 |
Millennium Management
New York
|
-$777K |
| 4 |
Morgan Stanley
New York
|
-$674K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$651K |
TARO Hedge Fund Activity: Q2 2023 in Review
71 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q2 2023, worth a combined $186M — up 85% from $101M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TARO positions and 14 closed out — a net gain of 9 holders — while 22 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $13.3M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $1.9M.
- 71 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q2 2023, up from 62 in Q1 2023.
- Funds reported $186M of Taro Pharmaceutical Industries Ltd. stock for Q2 2023, up 85% quarter-over-quarter.
- 23 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q2 2023 and 14 closed out, a net change of +9 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q2 2023 was BlackRock, an estimated $13.3M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q2 2023 was Hotchkis & Wiley Capital Management, an estimated $1.9M sold.
Based on aggregated 13F filings for Q2 2023.